多瑞医药：目前公司创新药研发以合作研发为主

Core Viewpoint - Duori Pharmaceutical is primarily focused on collaborative research and development of innovative drugs, with a promising market outlook for its product Yilung Jisheng Granules, which has completed Phase II clinical trial enrollment as of the end of December 2024 [1] Group 1 - The company has reported that the research and development progress of Yilung Jisheng Granules is proceeding smoothly [1] - The specific timeline for the product's market launch remains uncertain, and the company will fulfill its information disclosure obligations in accordance with relevant regulations [1]